Merck targets BMS' stomach cancer head start with Keytruda win, but past failure casts shadow

Merck targets BMS' stomach cancer head start with Keytruda win, but past failure casts shadow

Source: 
Fierce Pharma
snippet: 

Merck & Co.’s Keytruda has risen from the ashes with a positive stomach cancer trial readout. But there’s some reconciliation to do with a past failure that led to the withdrawal of an accelerated approval.